SG11201809714TA - Piperidines as menin inhibitors - Google Patents
Piperidines as menin inhibitorsInfo
- Publication number
- SG11201809714TA SG11201809714TA SG11201809714TA SG11201809714TA SG11201809714TA SG 11201809714T A SG11201809714T A SG 11201809714TA SG 11201809714T A SG11201809714T A SG 11201809714TA SG 11201809714T A SG11201809714T A SG 11201809714TA SG 11201809714T A SG11201809714T A SG 11201809714TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ann arbor
- co7d
- apartment
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330350P | 2016-05-02 | 2016-05-02 | |
| PCT/US2017/030577 WO2017192543A1 (en) | 2016-05-02 | 2017-05-02 | Piperidines as menin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809714TA true SG11201809714TA (en) | 2018-11-29 |
Family
ID=58699299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809714TA SG11201809714TA (en) | 2016-05-02 | 2017-05-02 | Piperidines as menin inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10899738B2 (ko) |
| EP (1) | EP3452461B1 (ko) |
| JP (1) | JP6991585B2 (ko) |
| KR (1) | KR20190015275A (ko) |
| CN (1) | CN109415337B (ko) |
| AU (1) | AU2017259436B2 (ko) |
| BR (1) | BR112018072570A2 (ko) |
| CA (1) | CA3022868A1 (ko) |
| ES (1) | ES2899936T3 (ko) |
| IL (2) | IL262697B (ko) |
| MX (1) | MX2018013433A (ko) |
| SG (1) | SG11201809714TA (ko) |
| WO (1) | WO2017192543A1 (ko) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| JP6919977B2 (ja) | 2016-03-16 | 2021-08-18 | クラ オンコロジー，インク． | メニン−ｍｌｌの置換された阻害剤及びその使用方法 |
| AU2017235462B2 (en) | 2016-03-16 | 2021-07-01 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| US10611778B2 (en) | 2016-09-14 | 2020-04-07 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
| EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
| JP7142010B2 (ja) | 2016-12-15 | 2022-09-26 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のアゼパン阻害剤 |
| EP3601249A4 (en) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA |
| EP3600313A4 (en) | 2017-03-31 | 2020-09-23 | The Regents of The University of Michigan | PIPERIDINES AS COVALENT MENINE INHIBITORS |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| JP7239562B2 (ja) | 2018-03-30 | 2023-03-14 | 住友ファーマ株式会社 | 光学活性な架橋型環状２級アミン誘導体 |
| AU2019243587A1 (en) * | 2018-03-30 | 2020-09-24 | The Regents Of The University Of Michigan | Piperidine compounds as covalent menin inhibitors |
| CN113164443A (zh) * | 2018-09-26 | 2021-07-23 | 库拉肿瘤学公司 | 用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤 |
| SG11202101733TA (en) | 2018-10-03 | 2021-03-30 | Univ Michigan Regents | Small molecule menin inhibitors |
| EP3906026A4 (en) | 2018-12-31 | 2022-10-19 | Biomea Fusion, LLC | IRREVERSIBLE MENIN-MLL INTERACTION INHIBITORS |
| CA3125353A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Inhibitors of menin-mll interaction |
| TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物 |
| WO2021204159A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
| TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| AU2022275192A1 (en) | 2021-05-08 | 2024-01-04 | Janssen Pharmaceutica Nv | Substituted spiro derivatives |
| EP4334310A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| CA3214990A1 (en) * | 2021-05-12 | 2022-11-17 | Gerard M. Mcgeehan | Combinations for treatment of cancer |
| EP4347588A1 (en) | 2021-06-01 | 2024-04-10 | JANSSEN Pharmaceutica NV | Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives |
| CN117425659A (zh) | 2021-06-03 | 2024-01-19 | 詹森药业有限公司 | 哒嗪或被螺环胺取代的1,2,4-三嗪 |
| KR20240021808A (ko) | 2021-06-17 | 2024-02-19 | 얀센 파마슈티카 엔브이 | 암과 같은 질환의 치료를 위한 (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드 베실레이트 염 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| WO1998054167A1 (fr) | 1997-05-28 | 1998-12-03 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Composes d'indole |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| WO2008070303A2 (en) | 2006-10-19 | 2008-06-12 | The University Of Chicago | Therapeutics to inhibit mll-menin interaction for treating leukemia |
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| WO2011060321A1 (en) | 2009-11-16 | 2011-05-19 | Chdi, Inc. | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| AR082889A1 (es) | 2011-05-09 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones para la inhibicion de nampt |
| MX2015011576A (es) | 2013-03-13 | 2016-05-16 | Univ Michigan | Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos. |
| WO2014200479A1 (en) * | 2013-06-12 | 2014-12-18 | The Regents Of The University Of Michigan | Menin-mll inhibitors and methods of use thereof |
| US9212180B2 (en) | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| CN108779116A (zh) | 2015-12-22 | 2018-11-09 | 生命医药公司 | 多发性内分泌瘤蛋白-mll相互作用的抑制剂 |
| AU2017235462B2 (en) | 2016-03-16 | 2021-07-01 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| JP6919977B2 (ja) | 2016-03-16 | 2021-08-18 | クラ オンコロジー，インク． | メニン−ｍｌｌの置換された阻害剤及びその使用方法 |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| KR102436430B1 (ko) | 2016-06-10 | 2022-08-24 | 비타이 파마슈티컬즈, 엘엘씨 | 메닌-mll 상호 작용의 억제제 |
| IL265028B (en) | 2016-09-16 | 2022-09-01 | Vitae Pharmaceuticals Llc | Inhibitors of the menin-mil interaction |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| EP3601249A4 (en) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA |
| EP3600313A4 (en) | 2017-03-31 | 2020-09-23 | The Regents of The University of Michigan | PIPERIDINES AS COVALENT MENINE INHIBITORS |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
| JP7239562B2 (ja) | 2018-03-30 | 2023-03-14 | 住友ファーマ株式会社 | 光学活性な架橋型環状２級アミン誘導体 |
| CN113164443A (zh) | 2018-09-26 | 2021-07-23 | 库拉肿瘤学公司 | 用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤 |
-
2017
- 2017-05-02 JP JP2018557418A patent/JP6991585B2/ja active Active
- 2017-05-02 CN CN201780040586.6A patent/CN109415337B/zh not_active Expired - Fee Related
- 2017-05-02 WO PCT/US2017/030577 patent/WO2017192543A1/en unknown
- 2017-05-02 AU AU2017259436A patent/AU2017259436B2/en not_active Ceased
- 2017-05-02 US US16/098,147 patent/US10899738B2/en active Active
- 2017-05-02 KR KR1020187034933A patent/KR20190015275A/ko not_active Application Discontinuation
- 2017-05-02 SG SG11201809714TA patent/SG11201809714TA/en unknown
- 2017-05-02 MX MX2018013433A patent/MX2018013433A/es unknown
- 2017-05-02 BR BR112018072570A patent/BR112018072570A2/pt not_active IP Right Cessation
- 2017-05-02 EP EP17722968.9A patent/EP3452461B1/en active Active
- 2017-05-02 CA CA3022868A patent/CA3022868A1/en not_active Abandoned
- 2017-05-02 ES ES17722968T patent/ES2899936T3/es active Active
-
2018
- 2018-10-31 IL IL262697A patent/IL262697B/en active IP Right Grant
-
2020
- 2020-11-23 US US17/101,323 patent/US20210198237A1/en not_active Abandoned
-
2021
- 2021-03-02 IL IL281182A patent/IL281182A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL262697B (en) | 2021-04-29 |
| AU2017259436A1 (en) | 2018-12-20 |
| US20190152947A1 (en) | 2019-05-23 |
| US10899738B2 (en) | 2021-01-26 |
| BR112018072570A2 (pt) | 2019-02-19 |
| US20210198237A1 (en) | 2021-07-01 |
| MX2018013433A (es) | 2019-07-18 |
| CA3022868A1 (en) | 2017-11-09 |
| IL262697A (en) | 2018-12-31 |
| KR20190015275A (ko) | 2019-02-13 |
| CN109415337A (zh) | 2019-03-01 |
| WO2017192543A1 (en) | 2017-11-09 |
| EP3452461A1 (en) | 2019-03-13 |
| JP6991585B2 (ja) | 2022-01-12 |
| ES2899936T3 (es) | 2022-03-15 |
| EP3452461B1 (en) | 2021-09-08 |
| JP2019514950A (ja) | 2019-06-06 |
| AU2017259436B2 (en) | 2021-08-26 |
| CN109415337B (zh) | 2022-01-18 |
| IL281182A (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201808729WA (en) | Bet protein degraders | |
| SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201808728QA (en) | Mdm2 protein degraders | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201807708SA (en) | Estrogen receptor modulators | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |